about
Institutional shared resources and translational cancer researchCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewBiomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewPrognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.Molecular classification and novel targets in hepatocellular carcinoma: recent advancementsThe COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyIncreasing efficiency for estimating treatment-biomarker interactions with historical data.Data integration to prioritize drugs using genomics and curated data.Strategies for power calculations in predictive biomarker studies in survival dataAnalysis of DNA microarray expression dataIntegrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?Clinical trials for predictive medicine: new challenges and paradigmsClinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.Randomized clinical trials with biomarkers: design issues.How to develop treatments for biologically heterogeneous "diseases".Quantifying factors for the success of stratified medicine.DNA repair and personalized breast cancer therapyStatistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.Fool's gold, lost treasures, and the randomized clinical trial.Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction.Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.Use of archived specimens in evaluation of prognostic and predictive biomarkersA genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deteriorationSystems biology and cancer: promises and perilsAdaptive clinical trial designs in oncology.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.Genetic architecture of colorectal cancer.Moving from correlative science to predictive oncology.Assessing treatment-selection markers using a potential outcomes framework.Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.Study designs and statistical analyses for biomarker researchThe benefits of using genetic information to design prevention trialsGene-expression signature of vascular invasion in hepatocellular carcinoma.Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosisGenomic biomarkers for personalized medicine: development and validation in clinical studies
P2860
Q24288943-75AE7963-4E91-46E3-8533-46B258B46AA2Q26740067-F8437E7E-799F-4185-B18E-6683D99E7992Q26766584-F36D43EA-4BD2-48C6-B88C-C9AD6DB075ADQ27332109-3FC597A0-8EC5-4B56-8E31-933AFF78418CQ28383646-36880702-64EF-4ACC-A108-FC48B178E046Q30433023-AEDFD8EE-54AF-40BB-B7D6-78C8809B613EQ30433465-AD62ED40-5462-4F45-A92D-F066941F4F65Q30438089-8A74A17A-A670-4F0A-8129-1E88E55BFE90Q30438965-6281A371-48E6-4E24-B0A7-C25065F39703Q30826349-61017703-C980-4287-A7F1-BBD080BD433CQ31102946-71F547D4-DD12-498F-A263-7F1EEE263F04Q31132692-0D722F4C-311F-4A76-BDF8-06CF2D60351FQ33495831-EBC39B51-C922-437A-B512-7C10BF1811A6Q33517983-62D91F1B-2BD1-4AF4-807D-C8B65A93FD8DQ33696732-BB85ADB3-783F-496C-A8D8-AAFF8A1E78ABQ33775506-0466A2E9-1841-4DA7-BD2D-B6C27CC020A1Q34024227-CA910545-1C7A-4E4E-840D-E99257503049Q34057001-FF3057CB-08B7-45E3-8453-1C0A8C410FEBQ34228544-215C1C4D-1358-4CFA-8B5C-DAE2CA36973EQ34234936-258CC8AA-EE27-4467-B6EF-423929702267Q34397841-7FD84743-9B9F-4BD1-B66F-FC286CDC50BDQ34669260-FE4C252A-23F2-48F4-8A1E-E001859E685EQ34691058-1888B261-47A9-4822-A5BC-EADDEB44E9A9Q34993367-27FD04F6-D176-4DBB-A487-2BF42B84A575Q35007222-109A6FAC-08DE-4D84-B006-E933A5213B9AQ35107005-02967711-2E1F-4093-B4C5-46E8CDA919B1Q35167309-B9584DBE-BEEE-4E3B-BA0C-A9E695CD3D37Q35206844-5A5E6DF9-7979-4947-BC72-1E4701D05FDAQ35619104-F73ABDD6-D951-40FB-B9FE-C63C68723B81Q35653768-B2EC53DB-3483-432E-92FF-64474123E1D8Q35672166-ABB32107-B9DD-4B65-A993-12BDB3618DC5Q36053127-4F5A3F6C-AF42-418A-A38F-D134A4BED9F5Q36117650-DB6A3995-A090-435D-8047-FA3D2329EA70Q36157844-D5D43E45-7F89-433B-B4FE-AD0B29934022Q36225623-7AEBE52F-2397-49D5-9183-9C616E7C913DQ36239075-7FAC0FDE-6535-42EE-93CF-680342DFF2FFQ36742590-BC2BD3AC-4B0A-43F9-AE0F-E0A23CDAFC87Q36759564-512E8AFA-6AAC-448A-92F1-638AA7F99265Q36788468-9ACD5B1C-D3D5-4252-927A-EDD453883102Q36837848-3918E1FA-698E-4BD2-9027-0E8DD96374EE
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The use of genomics in clinical trial design.
@en
The use of genomics in clinical trial design.
@nl
type
label
The use of genomics in clinical trial design.
@en
The use of genomics in clinical trial design.
@nl
prefLabel
The use of genomics in clinical trial design.
@en
The use of genomics in clinical trial design.
@nl
P1476
The use of genomics in clinical trial design.
@en
P2093
Richard Simon
P304
P356
10.1158/1078-0432.CCR-07-4531
P407
P577
2008-10-01T00:00:00Z